Semeglutide API of Shenzhen JYMed accepted by the first batch of domestic NMPA and Registered in US FDA (DMF No. 036009) with status “A”.

A cikin Mayu 2022, Shenzhen JYMed Technology Co., Ltd. (wanda ake kira JYMed peptide) ya ƙaddamar da aikace-aikacen rajistar semaglutide API zuwa Hukumar Abinci da Magunguna ta Amurka (FDA) (lambar rajista DMF: 036009), Ya wuce. bitar mutunci, kuma halin yanzu shine "A". JYMed peptide ya zama ɗaya daga cikin rukunin farko na masana'antun API na semaglutide a China don wuce bitar FDA ta Amurka.

A ranar 16 ga Fabrairu, 2023, gidan yanar gizon hukuma na Cibiyar Nazarin Magunguna ta Gwamnatin Jiha ta sanar da cewa semaglutide API [lambar rajista: Y20230000037] rajista kuma Hubei JXBio Co., Ltd., wani reshen JYMed peptide, ya bayyana. karba. JYMed peptide ya zama ɗaya daga cikin masana'antun magunguna na farko waɗanda aka karɓi aikace-aikacen tallan wannan samfur a China.

Game da semaglutide
Semaglutide shine GLP-1 agonist mai karɓa wanda Novo Nordisk (Novo Nordisk) ya haɓaka. Magungunan na iya haɓaka metabolism na glucose ta hanyar ƙarfafa ƙwayoyin β na pancreatic don ɓoye insulin, kuma yana hana fitar da glucagon daga ƙwayoyin α pancreatic don rage azumi da sukarin jini bayan cin abinci. Bugu da kari, yana rage cin abinci ta hanyar rage sha'awa da rage narkewar ciki, wanda a karshe yana rage kitsen jiki da kuma taimakawa wajen rage kiba.
1. Bayanan asali
Daga tsarin tsari, idan aka kwatanta da liraglutide, babban canji na semaglutide shine cewa an ƙara AEEA guda biyu zuwa sashin gefe na lysine, kuma an maye gurbin palmitic acid da octadecanedioic acid. An maye gurbin Alanine da Aib, wanda ya kara tsawon rabin rayuwar semaglutide.

Siffar Tsarin Semaglutide

2. Alamu
1) Semaglutide na iya rage haɗarin cututtukan zuciya da jijiyoyin jini a cikin marasa lafiya tare da T2D.
2) Semaglutide yana rage yawan sukarin jini ta hanyar haɓaka ƙwayar insulin da rage ƙwayar glucagon. Lokacin da yawan sukarin jini ya yi yawa, ƙwayar insulin yana motsawa kuma ana hana fitowar glucagon.
3) Novo Nordisk PIONEER gwaji na asibiti ya nuna cewa gudanar da baki na semaglutide 1mg, 0.5mg yana da mafi kyawun tasirin hypoglycemic da asarar nauyi fiye da Trulicity (dulaglutide) 1.5mg, 0.75mg.
3) Semaglutide na baka shine katin kati na Novo Nordisk. Gudanar da baki sau ɗaya a rana na iya kawar da rashin jin daɗi da azabtarwa ta hankali ta hanyar allura, kuma ya fi liraglutide (alurar sau ɗaya a mako). Sakamakon hypoglycemic da asarar nauyi na magunguna na yau da kullun kamar , empagliflozin (SGLT-2) da sitagliptin (DPP-4) suna da kyau ga marasa lafiya da likitoci. Idan aka kwatanta da tsarin allura, ƙirar baka za su inganta sauƙin aikace-aikacen asibiti na semaglutide.

3. Takaitawa
Daidai ne saboda kyakkyawan aikinsa a cikin hypoglycemic, asarar nauyi, aminci da fa'idodin zuciya da jijiyoyin jini cewa semaglutide ya zama sabon matakin "sabon tauraro" tare da babbar kasuwa.